Bioxytran, Inc. announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to initiate clinical trials of ProLectin-M for the treatment of mild to moderate COVID-19 in standard risk patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.091 USD | +0.89% |
|
+8.46% | -39.33% |
1st Jan change | Capi. | |
---|---|---|
-39.33% | 16.13M | |
+19.44% | 125B | |
+20.01% | 114B | |
+22.53% | 26.73B | |
-23.72% | 19.43B | |
-17.63% | 16.22B | |
-19.87% | 15.33B | |
+55.81% | 14.2B | |
+8.76% | 14.42B | |
-48.79% | 14.33B |
- Stock Market
- Equities
- BIXT Stock
- News Bioxytran, Inc.
- Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M